This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
Why Is Phibro (PAHC) Down 13.3% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.
Why Is Phibro Animal (PAHC) Up 10.7% Since Its Last Earnings Report?
by Zacks Equity Research
Phibro Animal (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.
Zacks.com featured highlights include: Archer Daniels, Phibro Animal, NEXEO, Western Digital and Fortinet
by Zacks Equity Research
Zacks.com featured highlights include: Archer Daniels, Phibro Animal, NEXEO, Western Digital and Fortinet
5 Stocks Near 52-Week High: Is More Upside Left?
by Zacks Equity Research
These stocks have passed through a screen we ran to find those that are trading near their 52-week high levels and still have plenty of upside left.
Here's Why Phibro Animal Health is Worth a Buy Right Now
by Zacks Equity Research
Phibro Animal Health (PAHC) continues to boost investor confidence on the back of sturdy segmental performances.
5 Growth Stocks in MedTech Set to Scale Higher in 2018
by Zacks Equity Research
The U.S. MedTech markets have been riding high with merger and acquisitions in focus.
Phibro Animal Health (PAHC) Up 7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro Animal Health (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.
Should You Sell Phibro Animal Health (PAHC) Before Earnings?
by Zacks Equity Research
Given that Phibro Animal Health (PAHC) has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings.
Phibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails
by Zacks Equity Research
Phibro's (PAHC) Animal Health segment has been a key contributor to growth over the last few quarters. MFA remains soft in the United States due to sales decline of medically important antimicrobials.
Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife
by Zacks Equity Research
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View
by Zacks Equity Research
Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.
Phibro Animal Banks on Diverse Portfolio, Competition Rife
by Zacks Equity Research
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Phibro (PAHC) Down 2.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal Health Expands Globally Amid Tough Competition
by Zacks Equity Research
Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.
Phibro Animal Health & Zydus Cadila Plan to Expand in India
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India.
Health Care Battle Rages On: 2 MedTech Stocks to Buy
by Zacks Equity Research
Let's focus on two MedTech Stocks which are fundamentally strong amidst the volatile market condition.
Here's Why Phibro Animal Health Is Worth Buying Right Now
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC), has rallied 24.2% over the past three months, ahead of the S&P 500's mere 2.6% gain.
Phibro Animal Health (PAHC) Rides High on Solid Prospects
by Zacks Equity Research
On Jun 12, we issued an updated research report on NJ-based Phibro Animal Health Corporation (PAHC) ??? a leading global diversified animal health and mineral nutrition company.
Phibro Animal Health (PAHC) Up 10% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro Animal Health (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.